1Progress and achievements of incentive policy reform for innovative drugs in ChinaWANG Qi-wei, YE Ya-jing, GUO Wen1297-13022The establishment and development of multiple resolution mechanism of intellectual property infringement disputes in China's pharmaceutical industryZHU Jia-zhen, LI Jing, ZHANG Jing1303-13103Analysis on the quality control of active pharmaceutical ingredients of deuterated drugsSUN De-yang, LIU Yan, HUANG Hai-wei1311-13154Current situation and analysis of the review and approval for orphan drugs in ChinaCAO Yong-fang, TANG Xiang-yan, WU Zheng, ZHOU Gang1316-13205Clinical trial analysis of recombinant human coagulation factor ⅦWANG Yan-lin, YU Ai-ping, LU Shuang1321-13286Predictive analysis on quality markers of Gastrodiae Rhizoma based on quality control status,clinical application and network pharmacologyQI Yu-tong, MENG Shuo, PENG Qing, REN Jun-guo, ZHANG Miao, LIU Jian-xun1329-13387Progress of modern research on Xanthoceras sorbifolia Bunge and analysis of quality markers predictionZHANG Juan-juan, DUAN Ming-yu, SUN Yue-yang, YANG Xiu-juan, WANG Ming-wei, LI Shuo, WANG Zhi-yong, ZHENG Gui-sen1339-13498Retrospective cohort study on the curative effect of Tongluo Qutong ointment on cold-dampness type lumbar disc herniationHOU Zhi-hui, JIANG Xiao-meng, XING Chao-feng, SUN Xiao-hang, ZHANG Kai, ZHOU Ming-wu, CHEN Jia1350-13559Discussion on the status and development trends of patient centered clinical trialsFANG Zhong-jian, SHEN Jia-hui, WANG Ying-xia, ZHANG Liang, FAN Yu-lu, ZHU Si-qi, SHAO Rong, SHAO Ming-li1356-136110Investigation and analysis on the management status of document control in drug clinical trial institutionsCHEN Na, CAI Xue-ling, YE Sui-wen, PAN Yun-yun, ZENG Shen, LV Li-hong, SUN Ping-ping, DAI Jie, SHEN Jie, ZOU Yan-qin1362-136911Synergistic anti-tumor effect of donafenib combined with histone deacetylase inhibitor on hepatocarcinoma cell linesDAI Ya-feng, LI Hui, WU Di, LI Xiao-ting, ZHANG Peng-jun, ZHU Xu1370-138012Optimization of extraction process for Yinqiao Mabo Powder based on standard relation and fuzzy analytic hierarchy process combined with entropy weight methodSHI Yu-wen, DIAO Yuan-yuan, JIANG Meng-cheng, LIU Wei-peng, LI Na, JIA Ai-ling1381-138913Development of impurity reference substance for quetiapine fumarateLI Zeng-xin, ZHOU Xiao-li, ZHANG Jin-ze, LIU Wan-hui, YIN Li-hui1390-139514Data mining and analysis of adverse event signals of entrectinib based on US FDA adverse event reporting systemDING Chu-feng, WANG Yu-ting, WU Qi-min, ZHENG Jing-ping, MA Lin, SU Ling1396-140215Economic evaluation of Jintiange capsule in the treatment of postmenopausal osteoporosisPENG Nan, LI Shan-shan, YU Jiang-xia, GUAN Hai-jing1403-1408 